Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

PMG Research

Neither a doctor nor a teaching hospital

Research payments

$11,002,355

1,134 payments

Through program year 2025, PMG Research is reported as receiving $11,002,355 in research payments, across 1,134 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $97,059 4
2024 Research $920,725 205
2023 Research $594,724 85
2022 Research $295,023 168
2021 Research $5,637,083 95
2020 Research $2,491,691 256
2019 Research $966,049 321

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $7,574,973 87 payments
  2. GlaxoSmithKline, LLC. $934,346 456 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $783,634 5 payments
  4. Biogen, Inc. $602,410 8 payments
  5. AstraZeneca Pharmaceuticals LP $506,691 27 payments
  6. Seqirus USA Inc $190,511 405 payments
  7. Ucb SA $138,492 28 payments
  8. Grifols Therapeutics LLC $126,945 43 payments
  9. CSL Behring $42,341 34 payments
  10. Helsinn Healthcare SA $27,764 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $5,965,839 28 payments
  2. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $879,950 19 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $729,184 40 payments
  4. phase III efficacy for obesity - with T2DM $433,683 1 payment
  5. RSV Oa=Adj-002 $431,722 113 payments
  6. Zoster-049 $341,210 302 payments
  7. Phase III efficacy for obesity - without T2DM $289,555 1 payment
  8. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $259,335 2 payments
  9. A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) $216,071 10 payments
  10. A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. $190,511 405 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record